Bupropion is an antidepressant that has noradrenergic and dopaminergic effects, being a weak dopamine reuptake inhibitor. increasingly used as an adjuvant for the treatment of depression, which is rarely used in monotherapy. In this context, the aim of this study was to compile the literature and compare the effectiveness of the norepinephrine-dopamine reuptake inhibitor bupropion with selective serotonin reuptake inhibitors in the treatment of major depressive disorder. Sungo the results, which was performed and 147 patients, with an average age of 41.7 years, dividing them into three groups randomly to be treated with a different drug, the first with bupropion with 51 patients, the second with sertraline with 58 patients and the third with venlafaxine 65 patients. Regarding the rate of remission of symptoms, there was no statistical difference between the groups at week 10 of treatment. This review corroborates that there is a benefit of bupropion as an adjuvant in the treatment of patients who have depressive disorder and bipolar affective disorder. However, bupropion showed excellent results associated with antidepressants compared to other treatments with monotherapy, which did not reduce 50% of the Montgomery-Asberg depression scale score.